Tel Aviv - Delayed Quote ILA

Evogene Ltd. (EVGN.TA)

256.20 -3.00 (-1.16%)
At close: April 25 at 2:24 PM GMT+3

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in ILA.
NameTitlePayExercisedYear Born
Mr. Ofer Haviv CPA CEO & President 390k -- 1966
Dr. Nir Arbel Chief Product Officer 228k -- 1980
Dr. Brian Ember Chief Executive Officer of AgPlenus Ltd 287k -- 1976
Dr. Elran Hillel Haber M.B.A., Ph.D. Chief Executive Officer of Biomica Ltd 302k -- 1980
Mr. Amit Noam Capt. res. Chief Executive Officer of Lavie Bio Ltd. 136k -- 1982
Mr. Yaron Eldad Chief Financial Officer -- -- 1965
Mr. Mark Kapel Chief Technology Officer 276k -- 1977
Rachel Pomerantz Gerber Head of Investor Relations -- -- --
Mr. Sassi Masliah Vice President of Corporate Development 245k -- 1979
Ms. Liat Foigel Wejgman Vice President of Human Resources -- -- --

Evogene Ltd.

13 Gad Feinstein Street
Park Rehovot PO Box 4173
Rehovot, 7414002
Israel
972 8 931 1900 https://www.evogene.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
142

Description

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Corporate Governance

Evogene Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers